AbbVie Inc. $ABBV Shares Newly Bought by BFI Infinity Ltd.

BFI Infinity Ltd. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, Holdings Channel.com reports. The fund purchased 15,882 shares of the company’s stock, valued at approximately $4,155,000. AbbVie accounts for approximately 2.0% of BFI Infinity Ltd.’s portfolio, making the stock its 16th largest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Granite Islands Private Wealth LLC boosted its holdings in shares of AbbVie by 3.1% in the 3rd quarter. Granite Islands Private Wealth LLC now owns 9,068 shares of the company’s stock worth $2,365,000 after buying an additional 272 shares during the last quarter. Patriot Investment Management Group Inc. grew its position in AbbVie by 17.1% during the third quarter. Patriot Investment Management Group Inc. now owns 4,574 shares of the company’s stock valued at $1,197,000 after buying an additional 668 shares during the period. ACT Advisors LLC. grew its position in AbbVie by 6.7% during the third quarter. ACT Advisors LLC. now owns 1,801 shares of the company’s stock valued at $471,000 after buying an additional 113 shares during the period. Ellsworth Advisors LLC purchased a new stake in AbbVie during the third quarter worth about $245,000. Finally, NFSG Corp increased its holdings in AbbVie by 2.6% during the third quarter. NFSG Corp now owns 9,304 shares of the company’s stock worth $2,434,000 after buying an additional 238 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

AbbVie Price Performance

AbbVie stock opened at $285.32 on Friday. AbbVie Inc. has a one year low of $190.75 and a one year high of $291.40. The business has a fifty day moving average price of $262.74 and a 200-day moving average price of $239.22. The firm has a market capitalization of $504.10 billion, a P/E ratio of 80.60, a PEG ratio of 1.29 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on ABBV. Citigroup boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. UBS Group increased their target price on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research report on Tuesday, October 6th. Leerink Partners raised their price target on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Rothschild & Co Redburn lifted their price target on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, BNP Paribas Exane lifted their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.